乌鸦传媒

An investigational dual glucagon/GLP-1 receptor agonist helped people with obesity or overweight, but without diabetes, by 46 weeks in a phase II trial, Boehringer Ingelheim and Zealand Pharma announced.

As the World Health Organization conducts its first review of obesity management guidelines in over two decades, the organization's nutrition chief said that semaglutide (Wegovy) and other are "no silver bullet" for global obesity. (Reuters)

The Endocrine Society released a new scientific statement on in the pediatric population, as well as sexual and gender minority populations. (Journal of Clinical Endocrinology & Metabolism)

Closure of mesenteric defects during cut the incidence of reoperation for small bowel obstruction from 14.9% to 7.8% during 10-year follow-up. (JAMA Surgery)

A single dose of 100-mg MDMA in people with arginine vasopressin deficiency, formerly known as central diabetes insipidus. (The Lancet Diabetes & Endocrinology)

Families are amid a persisting shortage. (NPR)

People with type 2 diabetes and diminished occlusal support were able to by chewing properly following an implant-supported fixed restoration. (PLOS One)

Treatment with a novel liver-selective thyroid hormone receptor beta agonist helped patients with (NASH) achieve up to a 52% mean liver fat reduction by week 12 in a phase IIb trial, said Viking Therapeutics.

People with obesity who received GLP-1 receptor agonists had , a small study suggested. (Obesity)

A -- a class of endocrine-disrupting chemicals -- in household and industrial cleaning products is moving forward in California. (Environmental Working Group)

Comment